Latent TB Testing

Latent TB Testing

Latent TB Testing determines individuals with asymptomatic Mycobacterium tuberculosis infection who are likely to develop overt TB. Screening tests include the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs), which identify a body’s reaction to the bacteria. These tests are important in the prevention of TB epidemics among multiple risk groups such as the immunocompromised as well as the healthcare givers.

The Latent TB Testing Market is expected to grow with a significant CAGR of 7.8% during the forecast period (2024-2032). This is mainly due to the increasing rates of tuberculosis across the world increasing the need to detect latent TB to prevent active TB. Also, improvements in diagnostic tools like IGRAs increase the effectiveness and utilization in high-risk groups. In addition, TB control campaigns supported by the government and compulsory screening norms also contribute to the growth of the market.

• Based on the test type, the market is segmented into Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA). The Interferon Gamma Released Assay (IGRA) held a significant share of the market in 2023. The Interferon Gamma Released Assay (IGRA). It is implemented almost exclusively in high-income countries and among the populations in need of protection. Adding to this, IGRA is used by companies to provide new, more precise tests, such as QuantiFERON-TB and T-SPOT.TB, and to increase the efficiency of diagnostic process automation. They aim to cooperate with healthcare organizations to include IGRAs in regular check-ups and increase the availability of IGRAs via point of care. This technology has high relevance in the current and future healthcare systems since there is a great need for accurate diagnostic equipment.

On March 18, 2024, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.

• Based on application, the market is segmented into household contacts (HHC) of tuberculosis (TB) patients, people living with HIV (PLHIV), and others. People living with HIV are expected to grow with a significant CAGR during the forecast period (2024-2032). The PLHIV segment is one of the primary consumers in the latent TB testing market because such patients have a higher risk of developing active TB and, therefore, require regular and accurate tests. The recent expansion of tuberculosis diagnostics in HIV care programs worldwide has boosted the need for gender-precise and accurate tests such as IGRAs. Companies adopt by developing partnerships with HIV clinics and NGOs to deliver specific test solutions and by providing affordable easy-to-scale testing solutions to this risky group.
• Based on the end user, the market is segmented into diagnostic laboratories, hospitals/clinics, and academic & research institutions. Diagnostic Laboratories held a significant share of the market in 2023. Diagnostic laboratories are major players as the testing centers for latent TB, especially in urban and semi-urban settings. They enhance growth by expanding access to high-level diagnostic equipment and guaranteeing the accuracy of results. To support this segment, companies supply and install IGRA automation systems, implement solutions for efficient lab operations, and provide technology for easy integration of the results into the clinical environment.
• For a better understanding of the market adoption of Latent TB Testing, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is due to a high tuberculosis incidence rate, improved understanding of the disease, and national efforts to eliminate the disease. As per the World Health Organization, In 2022, eight countries accounted for more than two-thirds of global TB cases: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%). Adding to this, large-scale screening is being carried out in countries such as India and China with the help of international organizations. Examples include offering low-cost diagnostic solutions, forming alliances with government organizations, and increasing market coverage to areas that have limited access to the products. A shift from conventional TSTs to advanced IGRAs within the urban regions also supports the growth of the market.
• Some of the major players operating in the market include QIAGEN, Revvity, Abbott, BIOMÉRIEUX, Serum Institute of India Pvt. Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma.